[1]. Biological Aging and Survival Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Receiving Systemic Therapy
CLINICAL LUNG CANCER [巻]27 [号]3 [頁]115 -126 （2026年） [査読] 有
[DOI] [2]. Geriatric nutritional risk index in antifibrotic therapy can predict tolerability and mortality risk.
Scientific reports （2026年） [査読] 有
[3]. Cold inducible RNA binding protein promotes fibroblast activation and its inhibition represents a potential therapeutic target in pulmonary fibrosis.
Scientific reports [巻]16 [号]1 （2026年） [査読] 有
[4]. Clinical Characteristics and Prevalence of Apical Scarring at Chest CT in a Healthy Population.
Radiology. Cardiothoracic imaging [巻]8 [号]1 [頁]e250190 （2026年） [査読] 有
[DOI] [5]. Epidemiology of interstitial lung diseases in Japan: A nationwide database analysis.
Respiratory investigation [巻]64 [号]2 [頁]101367 -101367 （2026年） [査読] 無
[DOI] [6]. Antifibrotic therapy in familial idiopathic pulmonary fibrosis: a comparative cohort study
SCIENTIFIC REPORTS [巻]15 [号]1 （2025年） [査読] 有
[DOI] [7]. Survival benefit of immune checkpoint inhibitors for non-small cell lung cancer patients with interstitial lung diseases: a nationwide population-based study.
Thorax （2025年） [査読] 有
[DOI] [8]. Risk stratification of acute exacerbations by autoantibodies in patients with idiopathic interstitial pneumonia.
Scientific reports [巻]15 [号]1 [頁]35623 （2025年） [査読] 有
[9]. Olanzapine plus triple antiemetic therapy for prevention of carboplatin-induced nausea: a pooled analysis of two clinical trials
BMC CANCER [巻]25 [号]1 （2025年） [査読] 有
[DOI] [10]. Immune checkpoint inhibitor-related pneumonitis: From guidelines to the front lines.
Respiratory investigation [巻]63 [号]5 [頁]1002 -1011 （2025年） [査読] 有
[11]. Post-discontinuation Survival in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors: A Pooled Analysis of Prospective Cohort Studies.
JTO clinical and research reports [巻]6 [号]8 [頁]100847 （2025年） [査読] 有
[DOI] [12]. First-line durvalumab plus platinum-etoposide in Japanese patients with extensive-stage small-cell lung cancer.
Cancer treatment and research communications [巻]44 [頁]100972 （2025年） [査読] 有
[DOI] [13]. PAI-1 Inhibitor TM5441 Attenuates Emphysema and Airway Inflammation in a Murine Model of Chronic Obstructive Pulmonary Disease.
International journal of molecular sciences [巻]26 [号]15 （2025年） [査読] 有
[14]. Analysis of the relationship between bronchoalveolar lavage lymphocyte fraction and detailed autoimmune features in patients with idiopathic interstitial pneumonia.
Scientific reports [巻]15 [号]1 [頁]26295 （2025年） [査読] 有
[DOI] [15]. Long-acting muscarinic antagonist versus leukotriene receptor antagonist as additional treatment in uncontrolled asthma patients used inhaled corticosteroids and long-acting β2 adrenergic agonist: a randomized phase 2 screening trial.
Respiratory medicine and research [巻]88 [頁]101191 （2025年） [査読] 有
[16]. Incidence and clinical significance of acute exacerbation of interstitial lung disease in patients with primary Sjögren's syndrome.
Respiratory investigation [巻]63 [号]5 [頁]838 -843 （2025年） [査読] 有
[DOI] [17]. Alveolar Sarcoidosis Mimicking Idiopathic Interstitial Pneumonia Without Mediastinal Lymphadenopathy.
Respirology case reports [巻]13 [号]7 [頁]e70278 （2025年） [査読] 有
[DOI] [18]. Severe drug-induced interstitial lung disease after photoimmunotherapy with cetuximab-sarotalocan sodium in a patient with oropharyngeal cancer: A case report.
Respiratory medicine case reports [巻]57 [頁]102260 （2025年） [査読] 有
[DOI] [19]. Depression and its association with mortality in idiopathic pulmonary fibrosis: A real-world data analysis.
Respiratory medicine [頁]108185 （2025年） [査読] 有
[DOI] [20]. Prognostic value of computed tomography assessment of normal lung volume in upper lobe in idiopathic pleuroparenchymal fibroelastosis.
ERJ open research [巻]11 [号]3 （2025年） [査読] 有
[21]. Pulmonary Hyalinizing Granuloma With Favourable and Longitudinal Treatment Response.
Respirology case reports [巻]13 [号]4 [頁]e70184 （2025年） [査読] 有
[DOI] [22]. The Role of Arterial Stiffness as Assessed by the Cardio-Ankle Vascular Index in Patients with Chronic Obstructive Pulmonary Disease.
Respiratory medicine [頁]108078 （2025年） [査読] 有
[23]. Quantitative Assessment of Systemic Sclerosis-Related Interstitial Lung Disease via 3D-Imaging.
Respirology (Carlton, Vic.) （2025年） [査読] 有
[DOI] [機関リポジトリ][24]. Lethal co-expression intolerance underlies the mutually exclusive expression of ASCL1 and NEUROD1 in SCLC cells.
NPJ precision oncology [巻]9 [号]1 [頁]74 （2025年） [査読] 有
[DOI] [25]. Utility of serum Krebs von den Lungen-6 and surfactant protein-D levels for the diagnosis of immune checkpoint inhibitor-induced immune-related pneumonitis.
Respiratory investigation [巻]63 [号]3 [頁]259 -264 （2025年） [査読] 有
[26]. Outcomes of COVID-19 in the Omicron-predominant wave: large-scale real-world data analysis with a comparison to influenza.
Pneumonia (Nathan Qld.) [巻]17 [号]1 [頁]3 （2025年） [査読] 有
[27]. Association of interstitial lung abnormalities with cytotoxic agent-induced pneumonitis in patients with malignancy
RESPIRATORY MEDICINE [巻]237 （2025年） [査読] 有
[DOI] [28]. Prevalence and clinical features of progressive pulmonary fibrosis in patients with unclassifiable idiopathic interstitial pneumonia: A post hoc analysis of prospective multicenter registry.
Respiratory investigation [巻]63 [号]2 [頁]216 -223 （2025年） [査読] 有
[DOI] [29]. 3D-CT-derived lung volumes and mortality risk in patients with fibrotic hypersensitivity pneumonitis
ALLERGOLOGY INTERNATIONAL [巻]74 [号]1 [頁]78 -85 （2025年） [査読] 有
[DOI] [30]. Association of interstitial lung abnormalities with cytotoxic agent-induced pneumonitis in patients with malignancy.
Respiratory medicine [頁]107924 （2024年） [査読] 有
[31]. Association between the HAL score and the development of progressive pulmonary fibrosis in idiopathic interstitial pneumonia: A prospective observational study.
Respiratory investigation [巻]63 [号]1 [頁]138 -145 （2024年） [査読] 有
[32]. Difference in efficacy of osimertinib between patients with EGFR-positive NSCLC with postoperative recurrence and those with de novo unresectable disease: A prospective, observational study.
Lung cancer (Amsterdam, Netherlands) [巻]198 [頁]108037 （2024年） [査読] 有
[33]. Factors Associated with Uncontrolled Severe Asthma in the Biologic Era.
Respiratory medicine [頁]107881 （2024年） [査読] 有
[DOI] [34]. Hypnotics and Mortality in Idiopathic Pulmonary Fibrosis: Hospital and National Data-Based Analysis.
Chest （2024年） [査読] 有
[DOI] [35]. Association of constipation with the survival of patients with idiopathic interstitial pneumonias.
Respiratory investigation [巻]62 [号]6 [頁]1204 -1208 （2024年） [査読] 有
[36]. Risk factors for relapse of immune-related pneumonitis after 6-week oral prednisolone therapy: a follow-up analysis of a phase II study.
BMC pulmonary medicine [巻]24 [号]1 [頁]495 （2024年） [査読] 有
[DOI] [37]. CXCL10 predicts autoimmune features and a favorable clinical course in patients with IIP: post hoc analysis of a prospective and multicenter cohort study.
Respiratory research [巻]25 [号]1 [頁]346 （2024年） [査読] 有
[38]. Case of familial interstitial lung disease attributed to ATP-binding cassette transporter 3 gene mutation in identical twins.
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG [巻]41 [号]3 [頁]e2024033 （2024年） [査読] 有
[39]. Multifaceted analysis of serum biomarkers for autoimmune features in patients with idiopathic interstitial pneumonia: A post-hoc analysis of prospective multicenter cohort study
EUROPEAN RESPIRATORY JOURNAL [巻]64 （2024年） [査読] 有
[DOI] [40]. Olanzapine Plus Triple Antiemetic Therapy for the Prevention of Carboplatin-Induced Nausea and Vomiting: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial
JOURNAL OF CLINICAL ONCOLOGY [巻]42 [号]23 （2024年） [査読] 有
[DOI] [41]. Obesity impairs ciliary function and mucociliary clearance in the murine airway epithelium.
American journal of physiology. Lung cellular and molecular physiology （2024年） [査読] 有
[DOI] [42]. Antifibrotics and mortality in idiopathic pulmonary fibrosis: external validity and avoidance of immortal time bias.
Respiratory research [巻]25 [号]1 [頁]293 （2024年） [査読] 有
[DOI] [43]. Cardiovascular safety of pimitespib in patients with advanced solid tumors: An open-label, nonrandomized, phase 1 study.
Cancer （2024年） [査読] 有
[DOI] [44]. 【ICIおよび分子標的治療薬の有害事象とその対策】肺障害
腫瘍内科 (有)科学評論社 [巻]33 [号]6 [頁]524 -524-530 （2024年） [査読] 無
[45]. Prevalence and Clinical Significance of Pulmonary Progressive Fibrosis in Myositis-associated Interstitial Lung Disease
American Journal of Respiratory and Critical Care Medicine [巻]209 [号]Supple [頁]A2847 （2024年） [査読] 無
[46]. CD109 Attenuates Bleomycin-induced Pulmonary Fibrosis by Inhibiting TGF-β Signaling
CD109 Attenuates Bleomycin-induced Pulmonary Fibrosis by Inhibiting TGF-β Signaling [巻]209 [号]supple [頁]A5191 （2024年） [査読] 無
[47]. 3D-CT Assessment of Normal Upper-lobe Lung Volume in Patients With Idiopathic Pleuroparenchymal Fibroelastosis
American Journal of Respiratory and Critical Care Medicine [巻]209 [号]supple [頁]A3699 （2024年） [査読] 無
[48]. Standardized 3D-CT lung volumes for patients with acute exacerbation of rheumatoid arthritis-associated interstitial lung disease.
Rheumatology (Oxford, England) [巻]63 [号]4 [頁]1162 -1171 （2024年） [査読] 有
[49]. Characterization of Mutation as a Targetable Driver Mutation Identified in Lung Adenocarcinoma by Comprehensive Genomic Profiling.
JCO precision oncology [巻]8 [頁]e2300538 （2024年） [査読] 有
[DOI] [機関リポジトリ][50]. 自己免疫特徴を有する間質性肺炎のサブタイプによる放射線学的および組織学的特徴、および治療反応：前向き、多施設コホート研究
Respiratory medicine [巻]224 [頁]107577 （2024年） [査読] 有
[DOI] [51]. ChatGPT CD109は、TGF-βシグナリングを抑制することで、ブレオマイシンによる肺線維症を軽減する
Journal of immunology (Baltimore, Md. : 1950) [巻]212 [号]7 [頁]1221 -1231 （2024年） [査読] 有
[DOI] [52]. 抗線維化療法を受けている患者における好中球-リンパ球と死亡リスクの関連
Respiratory medicine [巻]223 [頁]107542 （2024年） [査読] 有
[DOI] [53]. びまん性肺疾患 治療 免疫関連肺臓炎に対するプレドニゾロン6週間漸減法 単群第II相試験のフォローアップデータによる再燃リスクの解析
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]13 [号]増刊 [頁]211 -211 （2024年） [査読] 無
[54]. 早期パンデミックからデルタ株流行期にかけてのCOVID-19患者における、既存の間質性肺疾患が死亡率に与える影響：国内データベース研究
RESPIRATORY RESEARCH [巻]25 [号]1 （2024年） [査読] 有
[DOI] [55]. CLEC10Aの発現は、マウス肺における機能的に異なるサブセットの典型的なタイプ2樹状細胞（cDC2）を定義する
Allergology international : official journal of the Japanese Society of Allergology （2024年） [査読] 有
[DOI] [56]. Prognostic Role of Interferon-λ3 in Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis-Associated Interstitial Lung Disease
ARTHRITIS & RHEUMATOLOGY （2024年） [査読] 有
[DOI] [機関リポジトリ][57]. 特発性間質性肺炎患者の生存率と肺免疫予後指数の関連
RESPIROLOGY [巻]29 [号]2 [頁]136 -145 （2024年） [査読] 有
[DOI] [58]. 免疫チェックポイント阻害療法の直後に続く後続治療を受ける患者における抗腫瘍療法による間質性肺疾患のがん横断的評価
RESPIRATORY RESEARCH [巻]25 [号]1 （2024年） [査読] 有
[DOI] [59]. 高解像度CTにおける肺サルコイドーシスにおける"Bull's-eye"サインとその長期的な変化
American journal of respiratory and critical care medicine [巻]209 [号]1 [頁]e1-e3 （2024年） [査読] 有
[DOI] [60]. 特発性PPFE患者における好中球-リンパ球比
BMJ OPEN RESPIRATORY RESEARCH [巻]10 [号]1 （2023年） [査読] 有
[DOI] [61]. Changes in the characteristics and outcomes of COVID-19 patients from the early pandemic to the delta variant epidemic: a nationwide population-based study.
Emerging microbes & infections [巻]12 [号]1 [頁]2155250 （2023年） [査読] 有
[DOI] [62]. Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy.
Cancer immunology, immunotherapy : CII [巻]72 [号]8 [頁]2717 -2728 （2023年） [査読] 有
[63]. 高齢者栄養リスク指数は、特発性肺線維症患者における抗線維化療法の耐容性および死亡リスクの予測因子となる
RESPIROLOGY [巻]28 [号]8 [頁]775 -783 （2023年） [査読] 有
[DOI] [64]. 非小細胞肺癌患者に対する抗PD-1/PD-L1阻害療法において循環IL-6およびIL-15の存在が予後を分類する要因
CANCER IMMUNOLOGY IMMUNOTHERAPY [巻]72 [号]8 [頁]2717 -2728 （2023年） [査読] 有
[DOI] [65]. 急性増悪期のリウマチ性関節炎関連間質性肺疾患患者のための標準化された3D-CT肺容積
RHEUMATOLOGY （2023年） [査読] 有
[DOI] [66]. 免疫関連肺炎に対する6週間の経口プレドニゾロン療法：単群第II相研究
JOURNAL FOR IMMUNOTHERAPY OF CANCER [巻]11 [号]7 （2023年） [査読] 有
[DOI] [67]. 特発性間質性肺炎の急性増悪を予測するモデル
The European respiratory journal [巻]61 [号]5 [頁]2201634 （2023年） [査読] 有
[DOI] [機関リポジトリ][68]. 自己免疫特徴を持つ間質性肺炎の多面的な分析：前向き多施設コホート研究
Am J Respir Crit Care Med （2023年） [査読] 無
[69]. iPPFE患者における栄養失調関連リスクの評価
ERJ OPEN RESEARCH [巻]9 [号]3 （2023年） [査読] 有
[DOI] [70]. CD109 on Dendritic Cells Regulates Airway Hyperreactivity and Eosinophilic Airway Inflammation.
American journal of respiratory cell and molecular biology [巻]68 [号]2 [頁]201 -212 （2023年） [査読] 有
[DOI] [71]. Association between increased peripheral blood CD86-positive plasmacytoid dendritic cells and immune-related adverse events in patients with non-small cell lung cancer.
Global health & medicine [巻]4 [号]6 [頁]301 -308 （2022年） [査読] 有
[DOI] [72]. Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume.
The European respiratory journal [巻]60 [号]6 （2022年） [査読] 有
[DOI] [73]. Prognostic significance of radiological pleuroparenchymal fibroelastosis in complex lung disease: a multicentre retrospective cohort study.
Thorax （2022年） [査読] 有
[DOI] [74]. Clinical practice of high-flow nasal cannula therapy in COVID-19 pandemic era: a cross-sectional survey of respiratory physicians.
Respiratory investigation [巻]60 [号]6 [頁]779 -786 （2022年） [査読] 有
[DOI] [75]. 非小細胞肺癌におけるGeriatric Nutritional Risk Indexとニボルマブの有効性の関連
肺癌 (NPO)日本肺癌学会 [巻]62 [号]6 [頁]634 （2022年） [査読] 無
[76]. EGFRL858R変異遺伝子検出におけるddPCR法と比較したNOIR-SSの有用性
肺癌 (NPO)日本肺癌学会 [巻]62 [号]6 [頁]589 （2022年） [査読] 無
[77]. 非小細胞肺癌患者における血清免疫調整因子とアテゾリズマブ治療による免疫関連有害事象との関連
肺癌 (NPO)日本肺癌学会 [巻]62 [号]6 [頁]637 （2022年） [査読] 無
[78]. 小細胞肺癌の細胞分化に関わる転写因子の肺大細胞神経内分泌癌における意義
肺癌 (NPO)日本肺癌学会 [巻]62 [号]6 [頁]678 （2022年） [査読] 無
[79]. 非小細胞肺癌におけるGeriatric Nutritional Risk Indexとプラチナ併用化学療法の有効性の関連
肺癌 (NPO)日本肺癌学会 [巻]62 [号]6 [頁]756 （2022年） [査読] 無
[80]. Frequency, proportion of PF-ILD, and prognostic factors in patients with acute exacerbation of ILD related to systemic autoimmune diseases.
BMC pulmonary medicine [巻]22 [号]1 [頁]387 （2022年） [査読] 有
[DOI] [81]. COVID-19におけるHigh-flow nasal cannulaの使用実態 呼吸器内科医対象アンケート調査
日本呼吸ケア・リハビリテーション学会誌 (一社)日本呼吸ケア・リハビリテーション学会 [巻]32 [号]Suppl. [頁]180s （2022年） [査読] 無
[82]. An open-label, crossover study to compare different formulations and evaluate effect of food on pharmacokinetics of pimitespib in patients with advanced solid tumors.
Investigational new drugs [巻]40 [号]5 [頁]1011 -1020 （2022年） [査読] 有
[DOI] [83]. Effect of Hypoxia on Pulmonary Endothelial Cells from Bleomycin-Induced Pulmonary Fibrosis Model Mice.
International journal of molecular sciences [巻]23 [号]16 （2022年） [査読] 有
[DOI] [84]. 肺病変を伴う自己免疫性疾患 顕微鏡的多発血管炎に合併した間質性肺疾患と急性増悪:多施設共同研究
アレルギー (一社)日本アレルギー学会 [巻]71 [号]6-7 [頁]797 （2022年） [査読] 無
[85]. CD109分子は樹状細胞依存性に好酸球性気道炎症を制御する
アレルギー (一社)日本アレルギー学会 [巻]71 [号]6-7 [頁]862 （2022年） [査読] 無
[86]. Associations of serum long-chain fatty acids with multiple organ involvement in patients with sarcoidosis.
BMC pulmonary medicine [巻]22 [号]1 [頁]290 （2022年） [査読] 有
[DOI] [87]. Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer.
Journal of cancer research and clinical oncology （2022年） [査読] 有
[DOI] [88]. Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis
THORAX [巻]77 [号]7 [頁]727 -730 （2022年） [査読] 有
[DOI] [89]. Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis.
Respiratory research [巻]23 [号]1 [頁]142 （2022年） [査読] 有
[DOI] [90]. CD109 on Dendritic Cells Regulates Airway Hyperreactivity and Eosinophilic Airway Inflammation.
Am J Respir Crit Care Med [巻]205 [頁]A5007 （2022年） [査読] 無
[91]. Frequencies and Prognostic Factors of Acute Exacerbation of Systemic Autoimmune Disease-Related Interstitial Lung Diseases: A Retrospective Study.
Am J Respir Crit Care Med [巻]205 [頁]A3532 （2022年） [査読] 無
[92]. Acute Exacerbation of Rheumatoid Arthritis-Associated Interstitial Lung Disease: Prognostic Factors and Mortality Prediction Model.
Am J Respir Crit Care Med [巻]205 [頁]A3531 （2022年） [査読] 無
[93]. Combined Assessment of the GAP Index and Body Mass Index at Antifibrotic Therapy Initiation for Prognosis of Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med [巻]205 [号]A2430 （2022年） [査読] 無
[94]. Effects of long-acting muscarinic antagonists on promoting ciliary function in airway epithelium.
BMC pulmonary medicine [巻]22 [号]1 [頁]186 （2022年） [査読] 有
[DOI] [95]. Impact of end-of-life respiratory modalities on quality of dying and death and symptom relief in patients with interstitial lung disease: a multicenter descriptive cross-sectional study.
Respiratory research [巻]23 [号]1 [頁]79 （2022年） [査読] 有
[DOI] [96]. びまん性肺疾患 予後 GAP indexとBMI評価を抗線維化薬を導入するIPF患者の予後予測に活用する
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]140 （2022年） [査読] 無
[97]. びまん性肺疾患 予後 関節リウマチ関連間質性肺疾患の急性増悪:死亡率とその予測モデル
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]140 （2022年） [査読] 無
[98]. EGFR遺伝子変異陽性肺癌 Cell free DNAを用いたEGFR遺伝子変異アレル頻度の検討 NOIR-SSとddPCRの比較
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]141 （2022年） [査読] 無
[99]. びまん性肺疾患 疫学・統計 Interstitial Lung Abnormalitiesと細胞傷害性化学療法による薬剤性肺障害
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]147 （2022年） [査読] 無
[100]. 膠原病関連間質性肺疾患における急性増悪例の臨床像、治療および予後因子に関する後方視的研究
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]218 （2022年） [査読] 無
[101]. 肺大細胞神経内分泌がんにおける運命制御転写因子の意義
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]227 （2022年） [査読] 無
[102]. High-flow nasal cannulaの使用実態 呼吸器内科医師対象アンケート調査
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]237 （2022年） [査読] 無
[103]. Film Array呼吸器パネル2.1を用いた間質性肺疾患の成因に対するウイルス感染の関与の検討
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]247 （2022年） [査読] 無
[104]. CD109分子は樹状細胞依存性に好酸球性気道炎症を制御する
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]282 （2022年） [査読] 無
[105]. 過敏性肺炎・膠原病肺 多発性筋炎/皮膚筋炎に伴う間質性肺疾患における血清IFN-λ3の臨床的意義
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]151 （2022年） [査読] 無
[106]. 特発性間質性肺炎における血球分画比と予後の関連
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]245 （2022年） [査読] 無
[107]. 特発性間質性肺炎における便秘と予後の関連
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]268 （2022年） [査読] 無
[108]. 外科的肺生検が分類不能型間質性肺疾患の予後に与える影響
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]268 （2022年） [査読] 無
[109]. ALS患者におけるPleuroparenchymal fibroelastosis様所見の意義
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]270 （2022年） [査読] 無
[110]. 真菌感作喘息モデルマウスにおけるアスペルギルス単独感作とアスペルギルス・アルテルナリア重複感作の病態の比較
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]281 （2022年） [査読] 無
[111]. 関節リウマチに伴う間質性肺疾患急性増悪における3D-CT肺容積評価
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]11 [号]増刊 [頁]301 （2022年） [査読] 無
[112]. Impact of antifibrotic therapy on lung cancer development in idiopathic pulmonary fibrosis.
Thorax （2022年） [査読] 有
[DOI] [機関リポジトリ][113]. Effects of adding a neurokinin-1 receptor antagonist to 5 mg olanzapine, a 5-hydroxytryptamine-3 receptor antagonist, and dexamethasone for preventing carboplatin-induced nausea and vomiting: a propensity score-matched analysis.
BMC cancer [巻]22 [号]1 [頁]310 （2022年） [査読] 有
[DOI] [114]. Acute exacerbation of rheumatoid arthritis-associated interstitial lung disease: mortality and its prediction model.
Respiratory research [巻]23 [号]1 [頁]57 （2022年） [査読] 有
[DOI] [115]. Involvement of autophagy in exacerbation of eosinophilic airway inflammation in a murine model of obese asthma.
Autophagy [頁]1 -13 （2022年） [査読] 有
[DOI] [116]. Multiple organ infarction caused by aortic thrombus in a lung cancer patient with the mutation.
Respiratory medicine case reports [巻]36 [頁]101608 （2022年） [査読] 有
[DOI] [117]. Trimethoprim-sulfamethoxazole induced eosinophilic pneumonia: A case report.
Respiratory medicine case reports [巻]37 [頁]101632 （2022年） [査読] 有
[DOI] [118]. Chemotherapy for patients with advanced lung cancer with interstitial lung disease: a prospective observational study.
Therapeutic advances in chronic disease [巻]13 [頁]20406223221108395 （2022年） [査読] 有
[DOI] [119]. Increased serum cholesterol and long-chain fatty acid levels are associated with the efficacy of nivolumab in patients with non-small cell lung cancer.
Cancer immunology, immunotherapy [巻]71 [号]1 [頁]203 -217 （2022年） [査読] 有
[DOI] [120]. Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients.
European journal of clinical pharmacology [巻]78 [号]1 [頁]77 -87 （2022年） [査読] 有
[121]. EGFR-Mutated Lung Adenocarcinoma Successfully Treated With Osimertinib After Spontaneous Transformation to SCLC and Adenocarcinoma With Neuroendocrine Differentiation: Case Report
JTO clinical and research reports [巻]3 [号]1 [頁]100264 （2022年） [査読] 有
[DOI] [122]. Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report.
JTO clinical and research reports [巻]3 [号]1 [頁]100263 （2022年） [査読] 有
[DOI] [123]. Transient leukocytopenia following combination therapy for COVID-19.
Respiratory investigation [巻]60 [号]1 [頁]158 -161 （2022年） [査読] 有
[DOI] [124]. Impacts of cachexia progression in addition to serum IgG and blood lymphocytes on serum nivolumab in advanced cancer patients.
European journal of clinical pharmacology [巻]78 [号]1 [頁]77 -87 （2022年） [査読] 有
[DOI] [125]. Association of the Geriatric Nutritional Risk Index With the Survival of Patients With Non-Small Cell Lung Cancer After Nivolumab Therapy
JOURNAL OF IMMUNOTHERAPY [巻]45 [号]2 [頁]125 -131 （2022年） [査読] 有
[DOI] [126]. Association of the Geriatric Nutritional Risk Index with the survival of patients with non-small-cell lung cancer after platinum-based chemotherapy.
BMC pulmonary medicine [巻]21 [号]1 [頁]409 （2021年） [査読] 有
[DOI] [127]. Clinical Significance of Cold-Inducible RNA-Binding Protein in Idiopathic Pulmonary Fibrosis.
Chest [巻]160 [号]6 [頁]2149 -2157 （2021年） [査読] 有
[DOI] [機関リポジトリ][128]. 神経内分泌分化を伴う術後再発に対してオシメルチニブが有効であったEGFR遺伝子変異陽性肺腺癌の1例
肺癌 (NPO)日本肺癌学会 [巻]61 [号]7 [頁]1015 （2021年） [査読] 無
[129]. ALK融合遺伝子陽性の進行性大細胞肺癌の1例
肺癌 (NPO)日本肺癌学会 [巻]61 [号]7 [頁]1015 （2021年） [査読] 無
[130]. Response.
Chest [巻]160 [号]6 [頁]e683 -e685 （2021年） [査読] 無
[DOI] [131]. Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide
Cancer Treat Res Commun [巻]29 [頁]100493 （2021年） [査読] 有
[132]. Radiological pleuroparenchymal fibroelastosis-like lesion in idiopathic interstitial pneumonias.
Respiratory research [巻]22 [号]1 [頁]290 （2021年） [査読] 有
[DOI] [133]. MET Amplification and Efficacy of Nivolumab in Patients With NSCLC
JTO clinical and research reports [巻]2 [号]11 [頁]100239 （2021年） [査読] 有
[DOI] [134]. Serum S100A8 and S100A9 as prognostic biomarkers in acute exacerbation of idiopathic pulmonary fibrosis.
Respiratory investigation [巻]59 [号]6 [頁]827 -836 （2021年） [査読] 有
[DOI] [機関リポジトリ][135]. アファチニブによる薬剤性皮膚血管炎と考えた1例
日本皮膚科学会雑誌 (公社)日本皮膚科学会 [巻]131 [号]12 [頁]2609 （2021年） [査読] 無
[136]. Pharmacokinetics, Safety, and Efficacy of Trastuzumab Deruxtecan with Concomitant Ritonavir or Itraconazole in Patients with HER2-Expressing Advanced Solid Tumors.
Clinical cancer research [巻]27 [号]21 [頁]5771 -5780 （2021年） [査読] 有
[DOI] [137]. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer with uncommon histology: a propensity-score-matched analysis.
BMC pulmonary medicine [巻]21 [号]1 [頁]309 （2021年） [査読] 有
[DOI] [138]. プラチナ+エトポシド併用療法に対するG-CSF一次予防の有用性
肺癌 (NPO)日本肺癌学会 [巻]61 [号]6 [頁]710 （2021年） [査読] 無
[139]. 血中コレステロールおよび長鎖脂肪酸値は非小細胞肺がんにおけるニボルマブの有効性と関連する
肺癌 (NPO)日本肺癌学会 [巻]61 [号]6 [頁]678 （2021年） [査読] 無
[140]. 希な組織型の非小細胞肺癌における免疫チェックポイント阻害薬の有効性 傾向スコアマッチ解析
肺癌 (NPO)日本肺癌学会 [巻]61 [号]6 [頁]671 （2021年） [査読] 無
[141]. FISH法で同定されたPD-L1遺伝子コピー数を用いた進行非小細胞肺癌におけるニボルマブの治療効果予測
肺癌 (NPO)日本肺癌学会 [巻]61 [号]6 [頁]646 （2021年） [査読] 無
[142]. 経気管支鏡下クライオバイオプシーが診断に有用であった肉芽腫性肺疾患の3例
日本サルコイドーシス/肉芽腫性疾患学会雑誌 日本サルコイドーシス [巻]41 [号]1-2 [頁]76 -81 （2021年） [査読] 無
[DOI] [143]. 急性肺障害をきたしたサルコイドーシスの1剖検例
日本サルコイドーシス/肉芽腫性疾患学会雑誌 日本サルコイドーシス [巻]41 [号]サプリメント号 [頁]66 （2021年） [査読] 無
[144]. Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis.
Scientific reports [巻]11 [号]1 [頁]18579 （2021年） [査読] 有
[DOI] [145]. 長時間作用性抗コリン薬は気道上皮の線毛機能を促進する
アレルギー (一社)日本アレルギー学会 [巻]70 [号]6-7 [頁]855 （2021年） [査読] 無
[146]. 気管支喘息・多様な側面 真菌関連喘息におけるアスペルギルス単独感作とアスペルギルス・アルテルナリア重複感作の臨床像の比較
アレルギー (一社)日本アレルギー学会 [巻]70 [号]6-7 [頁]813 （2021年） [査読] 無
[147]. 長時間作用性抗コリン薬は気道上皮の線毛機能を促進する
アレルギー (一社)日本アレルギー学会 [巻]70 [号]6-7 [頁]855 （2021年）
[148]. Diagnostic and prognostic significance of serum angiopoietin-1 and -2 concentrations in patients with pulmonary hypertension.
Scientific reports [巻]11 [号]1 [頁]15502 （2021年） [査読] 有
[DOI] [149]. Comparative assessment of NOIR-SS and ddPCR for ctDNA detection of EGFR L858R mutations in advanced L858R-positive lung adenocarcinomas.
Scientific reports [巻]11 [号]1 [頁]14999 （2021年） [査読] 有
[DOI] [150]. Efficacy and safety of 5 mg olanzapine for nausea and vomiting management in cancer patients receiving carboplatin: integrated study of three prospective multicenter phase II trials.
BMC cancer [巻]21 [号]1 [頁]832 （2021年） [査読] 有
[DOI] [151]. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.
BMC pulmonary medicine [巻]21 [号]1 [頁]221 （2021年） [査読] 有
[DOI] [152]. Prognostic significance of peripheral blood monocyte and neutrophil counts in rheumatoid arthritis-associated interstitial lung disease.
Respiratory medicine [巻]182 [頁]106420 （2021年） [査読] 有
[DOI] [153]. Impaired Autophagy Exacerbates Eosinophilic Airway Inflammation in Murine Model of Obesity Asthma
American Journal of Respiratory and Critical Care Medicine [巻]203 [頁]A1398 （2021年） [査読] 無
[154]. Analysis of Serum Angiopoietin-1 and -2 Concentrations in Patients with Pulmonary Hypertension
American Journal of Respiratory and Critical Care Medicine [巻]203 [頁]A3573 （2021年） [査読] 無
[155]. Long Acting Muscarinic Antagonists Promote Ciliary Function in Airway Epithelium
American Journal of Respiratory and Critical Care Medicine [巻]203 [頁]A4521 （2021年） [査読] 無
[156]. Prognostic classification in acute exacerbation of idiopathic pulmonary fibrosis: a multicentre retrospective cohort study.
Scientific reports [巻]11 [号]1 [頁]9120 （2021年） [査読] 有
[DOI] [157]. Simple method for detecting idiopathic interstitial pneumonias by measuring vertical lung length on chest X-ray.
Scientific reports [巻]11 [号]1 [頁]7669 （2021年） [査読] 有
[DOI] [158]. Prognostic and Clinical Value of Cluster Analysis in Idiopathic Pleuroparenchymal Fibroelastosis Phenotypes.
Journal of clinical medicine [巻]10 [号]7 （2021年） [査読] 有
[DOI] [159]. Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: A randomized, open-label trial
RESPIROLOGY [巻]26 [号]4 [頁]370 -377 （2021年） [査読] 有
[DOI] [160]. 肺高血圧症例における血清Angiopoietin-1, -2濃度の有用性に関する検討
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]305 （2021年） [査読] 無
[161]. 肺神経内分泌がんに対するプラチナ+エトポシド療法におけるfilgrastim一次予防の有用性
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]295 （2021年） [査読] 無
[162]. サルコイドーシス患者の疾患活動性と脂肪酸の関連
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]262 （2021年） [査読] 無
[163]. ブレオマイシン誘発性肺線維症モデルマウスにおける肺血管内皮細胞と肺線維芽細胞の相互作用
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]258 （2021年） [査読] 無
[164]. 顕微鏡的多発血管炎に合併した間質性肺疾患と急性増悪
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]252 （2021年） [査読] 無
[165]. 多発性筋炎/皮膚筋炎に伴う間質性肺疾患(PM/DM-ILD)に対するPSL+CNI治療の効果予測因子
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]252 （2021年） [査読] 無
[166]. 胸部レントゲンにおけるvertical lung length測定 特発性間質性肺炎の簡易スクリーニング法
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]226 （2021年） [査読] 無
[167]. volumetric CTによる肺容積減少がIPFの予後に与える影響
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]225 （2021年） [査読] 無
[168]. 抗線維化薬がIPF患者の肺癌発症や急性増悪に与える影響
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]224 （2021年） [査読] 無
[169]. 非結核性抗酸菌症におけるPleuroparenchymal fibroelastosis様所見の意義
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]221 （2021年） [査読] 無
[170]. 低温誘導性RNA結合タンパクは特発性肺線維症の疾患進行や予後を予測する新規バイオマーカーである
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]218 （2021年） [査読] 無
[171]. 長時間作用型抗コリン薬による線毛運動促進作用の解析
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]212 （2021年） [査読] 無
[172]. 特発性肺線維症における不眠症と睡眠薬
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]191 （2021年） [査読] 無
[173]. 抗線維化薬の切り替えは有益か? 多施設後方視研究
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]177 （2021年） [査読] 無
[174]. インフルエンザ患者における肺炎および死亡の予測スコアの開発 静岡国保データベースを用いた大規模解析
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]173 （2021年） [査読] 無
[175]. IVIMおよび灌流MRIを用いた免疫チェックポイント阻害剤投与後の腫瘍評価
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]156 （2021年） [査読] 無
[176]. 3D-CT volumetryによる両上葉容積評価はiPPFE患者の予後予測に有用である
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]141 （2021年） [査読] 無
[177]. オートファジー低下はTSLP依存性に肥満喘息を悪化させる
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]134 （2021年） [査読] 無
[178]. 成人喘息患者におけるアスペルギルス単独感作群とアスペルギルス・アルテルナリア重複感作群の臨床像の比較
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]133 （2021年） [査読] 無
[179]. 間質性肺疾患終末期患者におけるHigh-flow nasal cannulaの使用
日本呼吸器学会誌 (一社)日本呼吸器学会 [巻]10 [号]増刊 [頁]128 （2021年） [査読] 無
[180]. Conventional type 2 lung dendritic cells are potent inducers of follicular helper T cells in the asthmatic lung.
Allergology international （2021年） [査読] 有
[DOI] [181]. Quality of dying and death in patients with interstitial lung disease compared with lung cancer: an observational study
THORAX [巻]76 [号]3 [頁]248 -255 （2021年） [査読] 有
[DOI] [182]. Clinical Significance of Interstitial Lung Disease and Its Acute Exacerbation in Microscopic Polyangiitis.
Chest （2021年） [査読] 有
[DOI] [機関リポジトリ][183]. Cluster analysis-based clinical phenotypes of idiopathic interstitial pneumonias: associations with acute exacerbation and overall survival
BMC PULMONARY MEDICINE [巻]21 [号]1 （2021年） [査読] 有
[DOI] [184]. Subcutaneous injection of interferon gamma therapy could be useful for anti-IFN-gamma autoantibody associated disseminated nontuberculous mycobacterial infection
JOURNAL OF INFECTION AND CHEMOTHERAPY [巻]27 [号]2 [頁]373 -378 （2021年） [査読] 有
[DOI] [機関リポジトリ][185]. Pneumothorax in Patients with Idiopathic Pleuroparenchymal Fibroelastosis: Incidence, Clinical Features, and Risk Factors
RESPIRATION [巻]100 [号]1 [頁]19 -26 （2021年） [査読] 有
[DOI] [186]. Erlotinib and bevacizumab in elderly patients >= 75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations
INVESTIGATIONAL NEW DRUGS [巻]39 [号]1 [頁]210 -216 （2021年） [査読] 有
[DOI] [機関リポジトリ][187]. Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receivingantifibrotictherapy
RESPIROLOGY [巻]26 [号]2 [頁]171 -179 （2021年） [査読] 有
[DOI] [機関リポジトリ][188]. Subcutaneous injection of interferon gamma therapy could be useful for anti-IFN-γ autoantibody associated disseminated nontuberculous mycobacterial infection.
Journal of infection and chemotherapy [巻]27 [号]2 [頁]373 -378 （2021年） [査読] 有
[DOI] [189]. Cause of mortality and sarcopenia in patients with idiopathic pulmonary fibrosis receiving antifibrotic therapy.
Respirology [巻]26 [号]2 [頁]171 -179 （2021年） [査読] 有
[DOI] [190]. Erlotinib and bevacizumab in elderly patients ≥75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Investigational new drugs [巻]39 [号]1 [頁]210 -216 （2021年） [査読] 有
[DOI] [191]. Predictors for bronchoalveolar lavage recovery failure in diffuse parenchymal lung disease.
Scientific reports [巻]11 [号]1 [頁]1682 （2021年） [査読] 有
[DOI] [192]. Palliative Care for Idiopathic Pulmonary Fibrosis Patients: Pulmonary Physicians' View
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT [巻]60 [号]5 [頁]933 -940 （2020年） [査読] 有
[DOI] [機関リポジトリ][193]. Leucine-Rich alpha(2)-Glycoprotein as a Potential Biomarker for Immune-related Colitis After Anti-PD-L1 Therapy: A Report of a Case Series
CLINICAL LUNG CANCER [巻]21 [号]6 [頁]E516 -E522 （2020年） [査読] 有
[DOI] [機関リポジトリ][194]. Influenza A virus enhances ciliary activity and mucociliary clearance via TLR3 in airway epithelium
RESPIRATORY RESEARCH [巻]21 [号]1 （2020年） [査読] 有
[DOI] [195]. Development of a novel T cell-oriented vaccine using CTL/Th-hybrid epitope long peptide and biodegradable microparticles, against an intracellular bacterium
MICROBIOLOGY AND IMMUNOLOGY [巻]64 [号]10 [頁]666 -678 （2020年） [査読] 有
[DOI] [196]. Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data
CANCER SCIENCE [巻]111 [号]10 [頁]3705 -3713 （2020年） [査読] 有
[DOI] [197]. Prognostic significance of forced vital capacity decline prior to and following antifibrotic therapy in idiopathic pulmonary fibrosis
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE [巻]14 （2020年） [査読] 有
[DOI] [198]. Disease course and prognosis of pleuroparenchymal fibroelastosis compared with idiopathic pulmonary fibrosis
RESPIRATORY MEDICINE [巻]171 （2020年） [査読] 有
[DOI] [機関リポジトリ][199]. Evaluation of Programmed Death Ligand 1 (PD-L1) Gene Amplification and Response to Nivolumab Monotherapy in Non-small Cell Lung Cancer
JAMA NETWORK OPEN [巻]3 [号]9 （2020年） [査読] 有
[DOI] [200]. Development of a Novel T-Cell-Oriented Vaccine, Which Is Composed of Biodegradable Microparticles and T-Cell-Hybrid Epitope Long Peptide, Against Intracellular Bacteria.
Am J Respir Crit Care Med （2020年） [査読] 有
[201]. Pleuroparenchymal Fibroelastosis (PPFE): Prognostic Concordance of Clinical Diagnosis, Acute Exacerbation, and Prognosis Comparison with IPF.
Am J Respir Crit Care Med （2020年） [査読] 有
[202]. Conventional Type 2 Lung Dendritic Cells in Asthma Mouse Model Significantly Induce Follicular Helper T Cells Than Conventional Type 1.
Am J Respir Crit Care Med （2020年） [査読] 有
[203]. PolyI:C and Influenza A Virus Promote Mucociliary Clearance via TLR3 Pathway.
Am J Respir Crit Care Med （2020年） [査読] 有
[204]. 14-3-3γ Protein: A Novel Serum Biomarker for Predicting Prognosis in Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med （2020年） [査読] 有
[205]. Mac-2 Binding Protein Glycosylation Isomer in Patients with Chronic Pulmonary Aspergillosis.
Am J Respir Crit Care Med （2020年） [査読] 有
[206]. Efficacy of Combination Therapy with Prednisolone and Calcineurin Inhibitor in Patients with Myositis-Associated Interstitial Lung Disease.
Am J Respir Crit Care Med （2020年） [査読] 有
[207]. Clinical Features and Prognosis of Acute Exacerbation of Unclassifiable Idiopathic Interstitial Pneumonia.
Am J Respir Crit Care Med （2020年） [査読] 有
[208]. Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors: A Multicenter Prospective Study
JOURNAL OF THORACIC ONCOLOGY [巻]15 [号]8 [頁]1317 -1327 （2020年） [査読] 有
[DOI] [機関リポジトリ][209]. Pneumothorax in connective tissue disease-associated interstitial lung disease
PLOS ONE [巻]15 [号]7 （2020年） [査読] 有
[DOI] [210]. Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis
RESPIROLOGY [巻]25 [号]7 [頁]743 -749 （2020年） [査読] 有
[DOI] [機関リポジトリ][211]. Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE [巻]14 （2020年） [査読] 有
[DOI] [212]. Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) [巻]143 [頁]47 -54 （2020年） [査読] 有
[DOI] [213]. Elucidation of the relationships of MET protein expression and gene copy number status with PD-L1 expression and the immune microenvironment in non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) [巻]141 [頁]21 -31 （2020年） [査読] 有
[DOI] [214]. Pulse oximetric saturation to fraction of inspired oxygen (SpO(2)/FIO2) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE [巻]14 （2020年） [査読] 有
[DOI] [215]. Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-acquired Pneumonia (vol 9, 18750, 2019)
SCIENTIFIC REPORTS [巻]10 [号]1 （2020年） [査読] 有
[DOI] [216]. Comprehensive assessment of multiple tryptophan metabolites as potential biomarkers for immune checkpoint inhibitors in patients with non-small cell lung cancer.
Clin Transl Once （2020年） [査読] 有
[217]. CD200 and CD200R1 are differentially expressed and have differential prognostic roles in non-small cell lung cancer
ONCOIMMUNOLOGY [巻]9 [号]1 （2020年） [査読] 有
[DOI] [218]. Quantitative LC-MS/MS method for nivolumab in human serum using IgG purification and immobilized tryptic digestion
ANALYTICAL METHODS [巻]12 [号]1 [頁]54 -62 （2020年） [査読] 有
[DOI] [219]. Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-acquired Pneumonia.
Scientific reports [巻]9 [号]1 [頁]18750 （2019年） [査読] 有
[DOI] [220]. 市中肺炎に対するレボフロキサシン・スイッチ療法の有効性・安全性の検討(Intravenous to Oral Levofloxacin Switch Therapy in Patients with Moderate Community-acquired Pneumonia: A Pilot Study)
新薬と臨牀 (株)医薬情報研究所 [巻]68 [号]12 [頁]1519 -1531 （2019年） [査読] 有
[221]. Successful classification of macrophage-mannose receptor CD206 in severity of anti-MDA5 antibody positive dermatomyositis associated ILD.
Rheumatology (Oxford, England) [巻]58 [号]12 [頁]2143 -2152 （2019年） [査読] 有
[DOI] [222]. Simultaneous Occurrence of Sarcoidosis and Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis in a Patient with Lung Cancer.
Internal medicine (Tokyo, Japan) [巻]58 [号]22 [頁]3299 -3304 （2019年） [査読] 有
[DOI] [223]. Synchronous Occurrence of Bazex Syndrome and Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome in a Patient with Lung Cancer.
Internal medicine (Tokyo, Japan) [巻]58 [号]22 [頁]3267 -3271 （2019年） [査読] 有
[DOI] [224]. Prognostic factors for primary Sjögren's syndrome-associated interstitial lung diseases.
Respiratory medicine [巻]159 [頁]105811 （2019年） [査読] 有
[DOI] [225]. Prognostic impact of an early marginal decline in forced vital capacity in idiopathic pulmonary fibrosis patients treated with pirfenidone.
Respiratory investigation [巻]57 [号]6 [頁]552 -560 （2019年） [査読] 有
[DOI] [226]. Clinical significance of serum S100 calcium-binding protein A4 in idiopathic pulmonary fibrosis.
Respirology (Carlton, Vic.) （2019年） [査読] 有
[DOI] [227]. Body composition changes successfully classify prognosis in patients with mycobacterium avium complex lung disease.
The Journal of infection [巻]79 [号]4 [頁]341 -348 （2019年） [査読] 有
[DOI] [228]. Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
Lung cancer (Amsterdam, Netherlands) [巻]134 [頁]202 -209 （2019年） [査読] 有
[DOI] [229]. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
The Journal of rheumatology [巻]46 [号]8 [頁]935 -942 （2019年） [査読] 有
[DOI] [230]. Efficacy of corticosteroid and intravenous cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: A propensity score-matched analysis.
Respirology (Carlton, Vic.) [巻]24 [号]8 [頁]792 -798 （2019年） [査読] 有
[DOI] [231]. Analysis of serum adiponectin and leptin in patients with acute exacerbation of idiopathic pulmonary fibrosis.
Scientific reports [巻]9 [号]1 [頁]10484 （2019年） [査読] 有
[DOI] [232]. Olanzapine-containing antiemetic therapy for the prevention of carboplatin-induced nausea and vomiting.
Cancer chemotherapy and pharmacology [巻]84 [号]1 [頁]147 -153 （2019年） [査読] 有
[DOI] [233]. Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Investigational new drugs [巻]37 [号]3 [頁]531 -537 （2019年） [査読] 有
[DOI] [234]. Physiological and morphological differences of airways between COPD and asthma-COPD overlap.
Scientific reports [巻]9 [号]1 [頁]7818 （2019年） [査読] 有
[DOI] [235]. Efficacy of Glucocorticoids and Calcineurin Inhibitors for Anti-aminoacyl-tRNA Synthetase Antibody-positive Polymyositis/dermatomyositis-associated Interstitial Lung Disease: A Propensity Score-matched Analysis.
The Journal of rheumatology [巻]46 [号]5 [頁]509 -517 （2019年） [査読] 有
[DOI] [236]. Methotrexate-associated Lymphoproliferative Disorder with Diffuse Ground-Glass Opacities.
American journal of respiratory and critical care medicine [巻]199 [号]8 [頁]1031 -1033 （2019年） [査読] 有
[DOI] [237]. Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia.
Journal of clinical pharmacy and therapeutics [巻]44 [号]1 [頁]62 -68 （2019年） [査読] 有
[DOI] [238]. Clinical features of three-dimensional computed tomography-based radiologic phenotypes of chronic obstructive pulmonary disease.
International journal of chronic obstructive pulmonary disease [巻]14 [頁]1333 -1342 （2019年） [査読] 有
[DOI] [239]. Once-daily fluticasone furoate/vilanterol combination versus twice-daily budesonide/formoterol combination in the treatment of controlled stable asthma: a randomized crossover trial.
Journal of asthma and allergy [巻]12 [頁]253 -261 （2019年） [査読] 有
[DOI] [240]. Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD.
International journal of chronic obstructive pulmonary disease [巻]14 [頁]1867 -1877 （2019年） [査読] 有
[DOI] [241]. Paraneoplastic Remitting Seronegative Symmetrical Synovitis with Pitting Edema Syndrome Should be Treated with Low-dose Prednisolone During Pembrolizumab Therapy: The Author's Reply.
Internal Medicine （2019年） [査読] 有
[242]. Heterogeneous MET gene copy number and EGFR mutation elicit discordant responses to crizotinib between primary and metastatic lesions in erlotinib-resistant lung adenocarcinoma.
Lung Cancer （2019年） [査読] 有
[243]. Frequency and clinical relevance of anti-cyclic citrullinated peptide antibody in idiopathic interstitial pneumonias
RESPIRATORY MEDICINE [巻]154 [頁]102 -108 （2019年）
[DOI] [244]. Correlation of the modified Medical Research Council dyspnea scale with airway structure assessed by three-dimensional CT in patients with chronic obstructive pulmonary disease.
Respiratory medicine [巻]146 [頁]76 -80 （2019年） [査読] 有
[DOI] [245]. Differences in airway structural changes assessed by 3-dimensional computed tomography in asthma and asthma-chronic obstructive pulmonary disease overlap.
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology [巻]121 [号]6 [頁]704 -710.e1 （2018年）
[DOI] [246]. An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases.
Internal medicine (Tokyo, Japan) [巻]57 [号]23 [頁]3423 -3427 （2018年）
[DOI] [247]. Differences in clinical features of acute exacerbation between connective tissue disease-associated interstitial pneumonia and idiopathic pulmonary fibrosis
CHRONIC RESPIRATORY DISEASE [巻]16 （2018年）
[DOI] [248]. IL-17A Attenuates IFN-λ Expression by Inducing Suppressor of Cytokine Signaling Expression in Airway Epithelium.
Journal of immunology (Baltimore, Md. : 1950) [巻]201 [号]8 [頁]2392 -2402 （2018年）
[DOI] [249]. Heterogeneous MET gene copy number and EGFR mutation elicit discordant responses to crizotinib between primary and metastatic lesions in erlotinib-resistant lung adenocarcinoma.
Lung cancer (Amsterdam, Netherlands) [巻]124 [頁]317 -319 （2018年）
[DOI] [250]. Distinct profile and prognostic impact of body composition changes in idiopathic pulmonary fibrosis and idiopathic pleuroparenchymal fibroelastosis.
Scientific reports [巻]8 [号]1 [頁]14074 （2018年）
[DOI] [251]. Prophylactic aprepitant is better than salvage for carboplatin-based chemotherapy: a propensity score-matched analysis.
Medical oncology (Northwood, London, England) [巻]35 [号]11 [頁]139 （2018年）
[DOI] [252]. Macrophage mannose receptor, CD206, predict prognosis in patients with pulmonary tuberculosis.
Scientific reports [巻]8 [号]1 [頁]13129 （2018年）
[DOI] [253]. Prognostic evaluation of serum ferritin in acute exacerbation of idiopathic pulmonary fibrosis.
The clinical respiratory journal [巻]12 [号]8 [頁]2378 -2389 （2018年）
[DOI] [254]. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
Medical oncology (Northwood, London, England) [巻]35 [号]7 [頁]108 （2018年）
[DOI] [255]. Neutrophil gelatinase-associated lipocalin in patients with sarcoidosis.
Respiratory medicine [巻]138S [頁]S20 -S23 （2018年）
[DOI] [256]. Distinctive characteristics and prognostic significance of interstitial pneumonia with autoimmune features in patients with chronic fibrosing interstitial pneumonia.
Respiratory medicine [巻]137 [頁]167 -175 （2018年）
[DOI] [257]. Utility of serum Aspergillus-galactomannan antigen to evaluate the risk of severe acute exacerbation in chronic obstructive pulmonary disease.
PloS one [巻]13 [号]6 [頁]e0198479 （2018年）
[DOI] [258]. Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease.
Clinical medicine insights. Circulatory, respiratory and pulmonary medicine [巻]12 [頁]1179548418771702 （2018年）
[DOI] [259]. Clinical significance of myeloperoxidase-anti-neutrophil cytoplasmic antibody in idiopathic interstitial pneumonias.
PloS one [巻]13 [号]6 [頁]e0199659 （2018年）
[DOI] [260]. Clinical diagnosis of idiopathic pleuroparenchymal fibroelastosis: A retrospective multicenter study.
Respiratory medicine [巻]133 [頁]1 -5 （2017年）
[DOI] [261]. Persistent impairment on spirometry in chronic eosinophilic pneumonia: A longitudinal observation study (Shizuoka-CEP study).
Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology [巻]119 [号]5 [頁]422 -428.e2 （2017年）
[DOI] [262]. Clinical Utility of YKL-40 in Polymyositis/dermatomyositis-associated Interstitial Lung Disease.
The Journal of rheumatology [巻]44 [号]9 [頁]1394 -1401 （2017年）
[DOI] [263]. Synchronous Duodenal Cancer and Lung Cancer Harboring an Epidermal Growth Factor Receptor Mutation Treated with Erlotinib and Oral Fluoropyrimidine.
Internal medicine (Tokyo, Japan) [巻]56 [号]17 [頁]2367 -2371 （2017年）
[DOI] [264]. Relationship between fraction of exhaled nitric oxide and airway morphology assessed by three-dimensional CT analysis in asthma.
Scientific reports [巻]7 [号]1 [頁]10187 （2017年）
[DOI] [265]. Respiratory impedance is correlated with morphological changes in the lungs on three-dimensional CT in patients with COPD.
Scientific reports [巻]7 [頁]41709 （2017年）
[DOI] [266]. Clinical significance of soluble CD163 in polymyositis-related or dermatomyositis-related interstitial lung disease.
Arthritis research & therapy [巻]19 [号]1 [頁]9 （2017年）
[DOI] [267]. Successful crizotinib monotherapy in -mutant lung adenocarcinoma with acquired amplification after erlotinib therapy.
Respiratory medicine case reports [巻]20 [頁]160 -163 （2017年）
[DOI] [268]. Utility of Macrophage-activated Marker CD163 for Diagnosis and Prognosis in Pulmonary Tuberculosis.
Annals of the American Thoracic Society [巻]14 [号]1 [頁]57 -64 （2017年）
[DOI] [269]. Soluble hemoglobin scavenger receptor CD163 (sCD163) predicts mortality of community-acquired pneumonia.
The Journal of infection [巻]73 [号]4 [頁]375 -7 （2016年）
[DOI] [270]. Gastrointestinal Bleeding From Duodenal Aberrant Pancreas After Antiangiogenic Therapy.
Journal of clinical gastroenterology [巻]50 [号]8 [頁]689 -90 （2016年）
[DOI] [271]. Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer.
Investigational new drugs [巻]34 [号]4 [頁]490 -6 （2016年）
[DOI] [272]. Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy.
Medical oncology (Northwood, London, England) [巻]33 [号]7 [頁]65 （2016年）
[DOI] [273]. Increased levels of serum Wisteria floribunda agglutinin-positive Mac-2 binding protein in idiopathic pulmonary fibrosis.
Respiratory medicine [巻]115 [頁]46 -52 （2016年）
[DOI] [274]. Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer.
Lung cancer (Amsterdam, Netherlands) [巻]96 [頁]63 -7 （2016年）
[DOI] [275]. Changes in cross-sectional area of pulmonary vessels on chest computed tomography after chemotherapy in patients with advanced non-squamous non-small-cell lung cancer.
Cancer chemotherapy and pharmacology [巻]77 [号]5 [頁]1011 -8 （2016年）
[DOI] [276]. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
European journal of cancer (Oxford, England : 1990) [巻]58 [頁]30 -7 （2016年）
[DOI] [277]. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) [巻]90 [号]3 [頁]410 -6 （2015年）
[DOI] [278]. Clinicopathological and Survival Analysis of Japanese Patients with Resected Non-Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [巻]10 [号]11 [頁]1590 -600 （2015年）
[DOI] [279]. Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease.
Cancer chemotherapy and pharmacology [巻]76 [号]3 [頁]499 -505 （2015年）
[DOI] [280]. Management of brain metastasis with magnetic resonance imaging and stereotactic irradiation attenuated benefits of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer.
BMC cancer [巻]15 [頁]589 （2015年）
[DOI] [281]. Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Cancer chemotherapy and pharmacology [巻]76 [号]1 [頁]155 -61 （2015年）
[DOI] [282]. Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy.
Lung cancer (Amsterdam, Netherlands) [巻]84 [号]3 [頁]259 -64 （2014年）
[DOI] [283]. 健康な日本人ボランティアを対象にしたリファンピシン中止の時間的影響：カクテル法を用いたシトクロムP450活性に対する影響
Clinical pharmacology and therapeutics [巻]94 [号]6 [頁]702 -8 （2013年） [査読] 有
[DOI] [284]. Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study.
Cancer chemotherapy and pharmacology [巻]72 [号]2 [頁]445 -52 （2013年）
[DOI] [285]. Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: a randomized, phase-II study.
Lung cancer (Amsterdam, Netherlands) [巻]77 [号]3 [頁]550 -5 （2012年）
[DOI] [286]. Kaposi’s Sarcoma-Associated Virus Governs Gene Expression Profiles Toward B Cell Transformation. Herpesviridae- A Look Into This Unique Family of Viruses
A Look Into This Unique Family of Viruses InTech [頁]93 -104 （2012年） [査読] 有
[287]. IPF合併肺癌の治療. 放射線療法時の問題点.
日胸臨 [巻]70 [頁]823 -831 （2011年） [査読] 無
[288]. COPDの病因における自己免疫.
呼吸器内科 [巻]20 [頁]257 -263 （2011年） [査読] 無
[289]. Nonspecific Interstitial Pneumonia: Prognostic Significance of High-Resolution Computed Tomography in 59 Patients
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY [巻]35 [号]5 [頁]583 -589 （2011年）
[DOI] [290]. Antiendothelial Cell Antibodies in Patients With COPD.
Chest [巻]138 [号]6 [頁]1303 -8 （2010年）
[DOI] [291]. KSHV-infected PEL cell lines exhibit a distinct gene expression profile.
Biochemical and biophysical research communications [巻]394 [号]3 [頁]482 -7 （2010年）
[DOI] [292]. Accumulation of LANA at nuclear matrix fraction is important for Kaposi's sarcoma-associated herpesvirus replication in latency.
Virus research [巻]139 [号]1 [頁]74 -84 （2009年）
[DOI] [293]. 薬剤性肺障害の臨床. 漢方薬による薬剤性肺障害.
呼吸器科 [巻]12 [頁]145 -150 （2007年） [査読] 無
[294]. [Case of rapid progressive interstitial pneumonia associated with primary Sjogren syndrome].
Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society [巻]44 [号]10 [頁]721 -6 （2006年）
[295]. [A case of psittacosis showing a localized peripheral air-space consolidation].
Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society [巻]44 [号]9 [頁]670 -3 （2006年）
[296]. Pneumothorax in Patients with Idiopathic Pleuroparenchymal Fibroelastosis: Incidence, Clinical Features, and Risk Factors.
Respiration; international review of thoracic diseases [巻]100 [号]1 [頁]19 -26
[DOI] [297]. Association of the Geriatric Nutritional Risk Index With the Survival of Patients With Non-Small Cell Lung Cancer After Nivolumab Therapy.
Journal of immunotherapy (Hagerstown, Md. : 1997) [巻]45 [号]2 [頁]125 -131
[DOI]